Caixin
Jul 21, 2022 03:25 PM
TECH

Chinese Biotech Duo Eyes $2.8 Billion Singapore Expansion

Wuxi AppTec’s headquarters in Shanghai in 2019. Photo: VCG
Wuxi AppTec’s headquarters in Shanghai in 2019. Photo: VCG

Chinese contract drugmakers Wuxi AppTec Co. Ltd. and Wuxi Biologics Cayman Inc. have each unveiled a 10-year investment plan to expand their presence in Singapore — a boost to the Southeast Asian country’s effort to establish itself as a global biomedical manufacturing hub.

Wuxi Biologics was spun off from the large molecule drug subsidiary of Wuxi AppTec to list in Hong Kong in 2017. Already Shanghai-listed Wuxi AppTec landed in Hong Kong the following year.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: New ‘Langya’ Virus Detected in China
00:00
00:00/00:00